Guidelines for COVID-19 testing and quarantine of air travellers - Addendum to the Aviation Health Safety Protocol


Suggested citation: European Centre for Disease Prevention and Control and European Union Aviation Safety Agency. Guidelines for COVID-19 testing and quarantine of air travellers – Addendum to the Aviation Health Safety Protocol. 2 December 2020. ECDC: Stockholm; 2020.

This joint ECDC-European Union Aviation Safety Agency (EASA) document aims to support Member States in determining a coordinated approach to reduce the risks related to the movement of people by air within and between the EU/EEA countries and the UK in the context of the COVID-19 pandemic, noting that the impact of quarantine and testing is likely to vary according to levels of ongoing community transmission. It is intended to support decision-makers in the Member States, including public health authorities and civil aviation authorities, as well as aviation stakeholders, by providing an assessment of the current evidence on the likely impact of measures in respect of air travellers in different epidemiological situations. The recommendations outlined in this document may also be taken into account by Member States when considering temporary restrictions on non-essential travel to the EU in relation to residents of third countries. This document will be revised as new evidence emerges and in the light of likely future changes in the pandemic.

**Update 14 April 2021**
A SARS-CoV-2 variant of concern (VOC), B.1.1.7, is currently widely circulating in EU/EEA countries. Other VOCs have also been detected as sporadic cases or localised outbreaks.. ECDC has updated its guidance for COVID-19 on quarantine and testing of travellers and recommends that non-essential travel be avoided. In addition to recommendations against non-essential travel and restrictions on travel for those infected, travel measures such as the testing and quarantine of travellers can be considered, in particular, for travellers from areas with a higher incidence of variants with immune escape potential (e.g. B.1.135, or P.1). If sequencing is inadequate to exclude the possibility of a higher incidence of the new variants, as per ECDC guidance on genomic sequencing, proportionate travel measures should also be considered from areas where there is continued high level of community transmission.
Updates on the situation about VOC circulation can be found in the ECDC Weekly COVID-19 Country Overview report under Tab 3.7 ‘Variants of Concern’

Executive summary

This joint ECDC-European Union Aviation Safety Agency (EASA) document provides information on effective and differentiated strategies to enable the health authorities to evaluate scenarios and make informed decisions on the best possible measures.

Scientific evidence and information, presented and analysed in this document, give rise to the following key considerations:

  • In the current epidemiological situation, where SARS-CoV-2 is established in all EU/EEA countries and the UK, imported cases account for a very small proportion of all detected cases and are unlikely to significantly increase the rate of transmission.
  • The prevalence of SARS-CoV-2 in travellers is estimated likely to be lower than the prevalence in the general population or among contacts of confirmed cases.
  • Travellers should not be considered as a high-risk population, nor treated as contacts of COVID-19 cases, unless they had been in known contact with a confirmed positive case.
  • Travellers should be subject to the same regulations or recommendations as applied to the local population.
  • Member States should always admit their own nationals and EU citizens and their family members resident in their territory, and should facilitate swift transit through their territories.

Decision makers are invited to consider the detailed epidemiological evidence that supports the options presented in this document acknowledging that:

  • In the current epidemiological situation, quarantine or systematic testing for SARS-CoV-2 of air travellers is not recommended.
  • Harmonisation among Member States is recommended based on the specific measures presented in this document.

Chapter 3 outlines the main risk assessment criteria and the available evidence and information on the use of testing and quarantine for travellers. Where scientific evidence is insufficient, the document takes into consideration modelling studies and expert opinions from the relevant experts at the European Centre for Disease Prevention and Control (ECDC) and the European Union Aviation Safety Agency (EASA).

In Chapter 4, the document presents specific operational recommendations for the management of these travel related measures by the Member States.

The document, its observations, recommendations and conclusions are based on the evidence and best knowledge available at the time of writing, as compiled and analysed by experts at ECDC and EASA. Depending on the evolution of the pandemic and future evidence and developments, in terms of risk assessment criteria, testing technologies or the introduction of vaccines, this document may require updating which may prompt further assessment by the Member States in their implementation efforts.

Latest ECDC risk assessment

Latest risk assessments on COVID-19

ECDC risk assessments aim at supporting the EU/EEA countries and the European Commission in their preparedness and response to a public health threat.

Related ECDC-EASA publication

COVID-19 Aviation Health Safety Protocol: Operational guidelines for the management of air passengers and aviation personnel in relation to the COVID-19 pandemic

The European Union Aviation Safety Agency (EASA) and the European Centre for Disease Prevention and Control (ECDC) have updated their joint Aviation Health Safety Protocol providing clear operational guidance and risk-based recommendations for health-safe air travel to complement the European Union’s initiatives, such as the EU Digital COVID Certificates.

Read more

Sequencing of SARS-CoV-2 - first update

This technical guidance aims to provide guidelines to laboratories and relevant stakeholders in the European Union (EU), European Economic Area (EEA) and other countries in the WHO European region in making decisions on establishing sequencing capacities and capabilities, in making decisions on which technologies to use and/or in deciding on the role of sequencing for SARS-CoV-2 diagnostics, research, outbreak investigations and surveillance.